Eversept Partners’s Agilon Health AGL Stock Holding History

Eversept Partners’s Portfolio AGL Stock Details AGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.05M	Sell	37,792 -138,796	-79%	-$9.09M	0.21%	74
2026 Q1	$1.4M	Buy	+176,588	New	+$2.86M	0.07%	99

Other funds holding AGL

CDR

Clayton Dubilier & Rice New York $895M AUM 792.56% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

NPCM

North Peak Capital Management New York $900M AUM 193.67% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

DCP

Durable Capital Partners Bethesda, Maryland $10.3B AUM 29.04% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Eversept Partners's AGL Position: Q2 2026 in Review

Eversept Partners reduced its Agilon Health (AGL) stake by 79% in Q2 2026, selling an estimated $9.09M and leaving 37,792 shares worth $4.05M. The position accounts for 0.21% of the portfolio, ranked #74.

Eversept Partners first reported a position in AGL in Q1 2026 and has held it in 2 quarters since. 179 funds tracked by Wall St. Rank hold AGL as of Q2 2026.

Eversept Partners held 37,792 shares of Agilon Health worth $4.05M as of Q2 2026.
Eversept Partners sold 138,796 Agilon Health shares in Q2 2026, an estimated $9.09M.
Agilon Health made up 0.21% of Eversept Partners's portfolio in Q2 2026, its #74 holding.
Eversept Partners first reported a position in Agilon Health in Q1 2026 and has held it in 2 quarters since.
179 funds tracked by Wall St. Rank held Agilon Health as of Q2 2026.

Based on Eversept Partners's 13F filing for Q2 2026, filed 14 Aug 2026.